Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icerguastat - InFlectis BioScience

Next Previous
Drug Profile

Icerguastat - InFlectis BioScience

Alternative Names: IFB-088; selective inhibitor of a holophosphatase - InFlectis BioScience; Sephin1

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical Research Council
  • Developer Assistance Publique - Hopitaux de Marseille; InFlectis BioScience; Qualissima; Stragen France SAS
  • Class Chlorobenzenes; Eye disorder therapies; Guanidines; Small molecules
  • Mechanism of Action PPP1R15A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Charcot-Marie-Tooth disease; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Preclinical Multiple sclerosis
  • No development reported Charcot-Marie-Tooth disease

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Charcot-Marie-Tooth-disease(In volunteers) in France (PO, Capsule)
  • 25 Nov 2022 Phase-II clinical trials in Amyotrophic lateral sclerosis (Combination therapy) in France (PO), after November 2022 (EudraCT2021-003875-32) (NCT05508074)
  • 28 Mar 2022 Icerguastat - InFlectis BioScience receives Orphan Drug status for Amyotrophic lateral sclerosis in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top